Professor David Richards is a Health Services Researcher at the forefront of national and international efforts to develop and test the low-intensity psychological treatments at the heart of the UK Department of Health's 'Improving Access to Psychological Therapies' (IAPT) programme in order to improve access to treatment for those suffering from high prevalence mental health problems such as depression.Clinical research group
Clinical research at Exeter brings together researchers with the common goal of advancing theoretical knowledge and clinical practice through basic and applied research. Our primary research area is in mood disorders: psychological processes implicated in unipolar and bipolar disorder and evidence-based approaches.
The work of the Clinical Psychology Research Group is based on a University – Health Service partnership that enables effective bridges between theory and clinical practice.
The Mood Disorders Centre is the platform for our clinical research group.
The group is enjoying a period of growth and expansion through significant successes in securing research funding, through the University’s investment in the group and through building bridges with the NHS and Peninsula College of Medicine and Dentistry.
The Mood Disorders Centre is committed to translating the best available knowledge about mood disorders to:
- develop evidence-based therapies;
- disseminate evidence-based therapies;
- improve access to psychological therapies.
Part of this commitment involves training clinical researchers and therapists in areas where we have developed expertise.
Exeter Graduate Fellow (EGF) studentships available for Oct 2012 entry
There are up to four Exeter Graduate Fellow (EGF) studentships available for applicants with an interest in researching the development, testing, evaluation and implementation of evidence-based psychological therapies. Find out more.
Our aim, put simply is to improve our understanding about mood disorders, to translate this understanding into therapeutic approaches and to improve access to high and low intensity evidence-based therapies.
